ASND Stock Analysis: Buy, Sell, or Hold?
ASND - Ascendis Pharma A/S American Depositary Shares
$274.50
6.71 (2.51%)
▲
5d:
+4.94%
30d:
+26.73%
90d:
+20.27%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When ASND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ASND is 12.4% above its trading range ($244.23). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ASND is 12.4% above its trading range ($244.23). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$163.05
Based on -6.8% avg growth
INTRINSIC VALUE TODAY
$101.24
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ASND is currently trading at $274.50, which is considered extended relative to its 30-day fair value range of $215.44 to $244.23. The stock's valuation (Forward PE: 29.1) is in line with its historical norms (31.2). Remarkably, the market is currently pricing in an annual earnings decline of 2.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ASND is showing sideways momentum. The price is approaching resistance at $274.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ASND has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ASND is showing sideways momentum. The price is approaching resistance at $274.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ASND has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$215.44 -
$244.23
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
47.6%
All Signals
- BEARISH: Price significantly overextended (+12.4% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($292.96)
Trading Range Analysis
30-Day Trading Range
$215.44 -
$244.23
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$222.82
Resistance Level
$274.89
Current Trend
Sideways
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
29.10
Wall Street Target
$292.96
(+6.7%)
Revenue Growth (YoY)
144.3%
Profit Margin
57.3%
Valuation Discount vs History
-2.3% cheaper
PE vs Historical
29.1 vs 31.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.3%
(market-implied from PE analysis)
1-Year Target
$268.19
(-2%)
2-Year Target
$262.02
(-5%)
3-Year Target
$255.99
(-7%)
3-Yr Target (if PE normalizes)
(PE: 29→31)
$274.45
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 29.1, Growth: -17.6%)
$200.11
(+-27%)
Base:
(SPY PE: 21.8, Growth: -17.6%)
$149.77
(-45%)
Bear:
(PE: 18.5, Growth: -17.6%)
$127.30
(-54%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (29x PE) as earnings recover.
Trailing PE: 31.30 | Current EPS (TTM): $8.62
Bull Case
$324.77
(+18%)
Analyst growth 9.4%, PE expands to 34.4
Base Case
$295.24
(+8%)
Market implied 9.4%, PE stable at 31.3
Bear Case
$183.47
(-33%)
Severe decline -20.0%, PE contracts to 26.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 29.1 to 31.2
Stabilization Target:
$294.29
(+7.2%)
PE Expansion Potential:
+7.2%
Share & Embed Analysis
Last updated: July 03, 2026 5:13 PM ET
Data refreshes hourly during market hours. Next update: 6:13 PM
Data refreshes hourly during market hours. Next update: 6:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
